| Basics |
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
|
| IPO Date: |
March 3, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.47B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.83%
|
| Avg Daily Range (30 D): |
$0.31 | 2.38%
|
| Avg Daily Range (90 D): |
$0.35 | 3.07%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.56M |
| Avg Daily Volume (30 D): |
2.27M |
| Avg Daily Volume (90 D): |
1.96M |
| Trade Size |
| Avg Trade Size (Sh.): |
87 |
| Avg Trade Size (Sh.) (30 D): |
91 |
| Avg Trade Size (Sh.) (90 D): |
90 |
| Institutional Trades |
| Total Inst.Trades: |
3,012 |
| Avg Inst. Trade: |
$2.29M |
| Avg Inst. Trade (30 D): |
$2.24M |
| Avg Inst. Trade (90 D): |
$2.25M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.86M |
| Avg Closing Trade (30 D): |
$3.8M |
| Avg Closing Trade (90 D): |
$3.66M |
| Avg Closing Volume: |
162.27K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.83
|
$-.98
|
|
Diluted EPS
|
|
$-.83
|
$-.98
|
|
Revenue
|
$
|
$ 37.96M
|
$ 20.04M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -71.85M
|
$ -84.85M
|
|
Operating Income / Loss
|
$
|
$ -69.35M
|
$ -83.76M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -45.36M
|
$ -.09M
|
|
PE Ratio
|
|
|
|
|
|
|
